20 June 2013
Keywords: bayer, takes, riociguat, into, phase, iii, germany-based
Article | 16 February 2009
Germany-based Bayer Schering Pharma has begun two Phase III trials with its oral, soluble guanylate cyclase agent riociguat in the
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
16 February 2009
2 March 2009
19 June 2013
© 2013 thepharmaletter.com